Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Total Current Liabilities (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Total Current Liabilities for 16 consecutive years, with $1.7 million as the latest value for Q1 2026.

  • Quarterly Total Current Liabilities rose 40.51% to $1.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Jan 2026, up 40.51% year-over-year, with the annual reading at $2.9 million for FY2025, 60.73% down from the prior year.
  • Total Current Liabilities for Q1 2026 was $1.7 million at PharmaCyte Biotech, up from $1.6 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $7.5 million in Q1 2024, with the low at $586581.0 in Q2 2023.
  • Average Total Current Liabilities over 5 years is $2.8 million, with a median of $1.5 million recorded in 2023.
  • The sharpest move saw Total Current Liabilities skyrocketed 1165.17% in 2024, then plummeted 85.8% in 2025.
  • Over 5 years, Total Current Liabilities stood at $1.3 million in 2022, then soared by 299.62% to $5.2 million in 2023, then decreased by 8.84% to $4.8 million in 2024, then plummeted by 66.97% to $1.6 million in 2025, then grew by 6.39% to $1.7 million in 2026.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $1.7 million, $1.6 million, and $1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.